A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer. 2009

Daris Ferrari, and Jessica Fiore, and Carla Codecà, and Giuseppe Di Maria, and Samuela Bozzoni, and Veronica Bordin, and Sarah Caldiera, and Andrea Luciani, and Sabrina Zonato, and Irene Floriani, and Paolo Foa
Division of Medical Oncology, San Paolo Hospital, Milan, Italy. daris.ferrari@ao-sanpaolo.it

The aim of this study was to investigate the activity and safety of a regimen containing carboplatin and paclitaxel in patients affected by recurrent or metastatic head and neck cancer. Eligible patients were treated with a 3-week combination of paclitaxel 175 mg/m2 and carboplatin area under the concentration time curve 5 mg/ml/min for a maximum of four cycles. A total of 27 patients entered the study. One patient (3.7%) had a complete response, whereas six patients (22.2%) obtained a partial response. Stable disease was observed in seven patients (25.9%). The disease control rate was 51.8% (95% confidence interval: 32.0-71.3), whereas overall response rate was 25.9% (95% confidence interval: 11.1-46.3). The median overall survival was 8.0 months (range: 2-27), with a 1-year survival of 30.5%. The median progression-free survival was 1.0 month (range: 0-14). Treatment-related deaths or episodes of neutropenic fever were not registered. Grades 3-4 neutropenia was observed in two patients (7.4%), grades 3-4 anaemia and thrombocytopenia in four (14.8%) and one (3.7%) patients, respectively. Nine patients (33.3%) experienced grades 1-2 and one patient (3.7%) grade 3 peripheral neuropathy. The combination of carboplatin and paclitaxel is safe and moderately effective for the treatment of recurrent or metastatic head and neck cancer.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D010523 Peripheral Nervous System Diseases Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves. Peripheral Nerve Diseases,Peripheral Neuropathies,PNS (Peripheral Nervous System) Diseases,PNS Diseases,Peripheral Nervous System Disease,Peripheral Nervous System Disorders,Nerve Disease, Peripheral,Nerve Diseases, Peripheral,Neuropathy, Peripheral,PNS Disease,Peripheral Nerve Disease,Peripheral Neuropathy
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006258 Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651) Cancer of Head and Neck,Head Cancer,Head Neoplasm,Head and Neck Cancer,Head and Neck Neoplasm,Neck Cancer,Neck Neoplasm,Neck Neoplasms,Neoplasms, Upper Aerodigestive Tract,UADT Neoplasm,Upper Aerodigestive Tract Neoplasm,Upper Aerodigestive Tract Neoplasms,Cancer of Head,Cancer of Neck,Cancer of the Head,Cancer of the Head and Neck,Cancer of the Neck,Head Neoplasms,Head, Neck Neoplasms,Neoplasms, Head,Neoplasms, Head and Neck,Neoplasms, Neck,UADT Neoplasms,Cancer, Head,Cancer, Neck,Cancers, Head,Cancers, Neck,Head Cancers,Neck Cancers,Neoplasm, Head,Neoplasm, Neck,Neoplasm, UADT,Neoplasms, UADT
D006402 Hematologic Diseases Disorders of the blood and blood forming tissues. Blood Diseases,Hematological Diseases,Blood Disease,Disease, Blood,Disease, Hematologic,Disease, Hematological,Diseases, Blood,Diseases, Hematologic,Diseases, Hematological,Hematologic Disease,Hematological Disease

Related Publications

Daris Ferrari, and Jessica Fiore, and Carla Codecà, and Giuseppe Di Maria, and Samuela Bozzoni, and Veronica Bordin, and Sarah Caldiera, and Andrea Luciani, and Sabrina Zonato, and Irene Floriani, and Paolo Foa
February 1997, Seminars in oncology,
Daris Ferrari, and Jessica Fiore, and Carla Codecà, and Giuseppe Di Maria, and Samuela Bozzoni, and Veronica Bordin, and Sarah Caldiera, and Andrea Luciani, and Sabrina Zonato, and Irene Floriani, and Paolo Foa
April 2001, Cancer,
Daris Ferrari, and Jessica Fiore, and Carla Codecà, and Giuseppe Di Maria, and Samuela Bozzoni, and Veronica Bordin, and Sarah Caldiera, and Andrea Luciani, and Sabrina Zonato, and Irene Floriani, and Paolo Foa
April 2002, Journal of chemotherapy (Florence, Italy),
Daris Ferrari, and Jessica Fiore, and Carla Codecà, and Giuseppe Di Maria, and Samuela Bozzoni, and Veronica Bordin, and Sarah Caldiera, and Andrea Luciani, and Sabrina Zonato, and Irene Floriani, and Paolo Foa
July 2008, Cancer chemotherapy and pharmacology,
Daris Ferrari, and Jessica Fiore, and Carla Codecà, and Giuseppe Di Maria, and Samuela Bozzoni, and Veronica Bordin, and Sarah Caldiera, and Andrea Luciani, and Sabrina Zonato, and Irene Floriani, and Paolo Foa
July 2012, Cancer chemotherapy and pharmacology,
Daris Ferrari, and Jessica Fiore, and Carla Codecà, and Giuseppe Di Maria, and Samuela Bozzoni, and Veronica Bordin, and Sarah Caldiera, and Andrea Luciani, and Sabrina Zonato, and Irene Floriani, and Paolo Foa
August 2018, Gynecologic oncology,
Daris Ferrari, and Jessica Fiore, and Carla Codecà, and Giuseppe Di Maria, and Samuela Bozzoni, and Veronica Bordin, and Sarah Caldiera, and Andrea Luciani, and Sabrina Zonato, and Irene Floriani, and Paolo Foa
October 2011, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
Daris Ferrari, and Jessica Fiore, and Carla Codecà, and Giuseppe Di Maria, and Samuela Bozzoni, and Veronica Bordin, and Sarah Caldiera, and Andrea Luciani, and Sabrina Zonato, and Irene Floriani, and Paolo Foa
July 2006, Head & neck,
Daris Ferrari, and Jessica Fiore, and Carla Codecà, and Giuseppe Di Maria, and Samuela Bozzoni, and Veronica Bordin, and Sarah Caldiera, and Andrea Luciani, and Sabrina Zonato, and Irene Floriani, and Paolo Foa
November 2005, Anti-cancer drugs,
Daris Ferrari, and Jessica Fiore, and Carla Codecà, and Giuseppe Di Maria, and Samuela Bozzoni, and Veronica Bordin, and Sarah Caldiera, and Andrea Luciani, and Sabrina Zonato, and Irene Floriani, and Paolo Foa
May 2009, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
Copied contents to your clipboard!